Garwood Medical Devices, an emerging Buffalo-based company developing groundbreaking BioPrax™ technology to treat antibiotic-resistant bacterial biofilm infections associated with metallic orthopaedic implants, announced today its Series C round of accredited-investor funding has closed at $4 million, as projected.

The third round of financing, which began last September, attracted institutional investment from groups such as The WNY Impact Investment Fund and the Murray family, former owners of UC Coatings, along with global investors in the orthopaedics/health care space.

Garwood Medical Devices, headquartered in Buffalo, NY was founded in July 2014. Garwood specializes in healthcare innovation and holds the exclusive license for the core BioPrax technology developed by the University at Buffalo. Its mission is to advance infection control through innovation.